{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:21:10Z","timestamp":1783704070309,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["BX20230444"],"award-info":[{"award-number":["BX20230444"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M734032"],"award-info":[{"award-number":["2023M734032"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303807"],"award-info":[{"award-number":["82303807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073396"],"award-info":[{"award-number":["82073396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["202206010141"],"award-info":[{"award-number":["202206010141"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.xcrm.2024.101414","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T15:34:49Z","timestamp":1707320089000},"page":"101414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"5","author":[{"given":"Yuxiang","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101414_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coi.2015.01.006","article-title":"The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?","volume":"33","author":"Shin","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","article-title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy","volume":"25","author":"Moran","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib3","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-14-1457","article-title":"Immuno-oncology combinations: a review of clinical experience and future prospects","volume":"20","author":"Antonia","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib4","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB\/CD137 Agonist, in Patients with Advanced Cancer","volume":"24","author":"Segal","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2008.00621.x","article-title":"The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer","volume":"222","author":"Lynch","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.xcrm.2024.101414_bib6","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2009-05-223958","article-title":"Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion","volume":"114","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101414_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/eji.201445388","article-title":"Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy","volume":"46","author":"Sanchez-Paulete","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1517\/14728222.2016.1091448","article-title":"Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies","volume":"20","author":"Vinay","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.xcrm.2024.101414_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A","article-title":"Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway","volume":"28","author":"Melero","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nm0402-343","article-title":"Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB","volume":"8","author":"Ye","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101414_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2024.101414_bib12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","article-title":"Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody","volume":"23","author":"Segal","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","article-title":"Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity","volume":"61","author":"Fisher","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2024.101414_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4738","article-title":"Twists and turns to translating 4-1BB cancer immunotherapy","volume":"11","author":"Sanmamed","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101414_bib15","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.xcrm.2024.101414_bib16","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-19-2958","article-title":"FS222, a CD137\/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models","volume":"26","author":"Lakins","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101414_bib18","article-title":"Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib19","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00262-010-0846-9","article-title":"Treatment with anti-CD137 mAbs causes intense accumulations of liver T\u00a0cells without selective antitumor immunotherapeutic effects in this organ","volume":"59","author":"Dubrot","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2024.101414_bib20","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-17-1847","article-title":"Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway","volume":"24","author":"Bartkowiak","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cyto.b.21259","article-title":"Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development","volume":"90","author":"Liang","year":"2016","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.xcrm.2024.101414_bib22","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/S1470-2045(23)00095-5","article-title":"REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment","volume":"24","author":"Ghorani","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101414_bib23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.xcrm.2024.101414_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.leu.2403675","article-title":"Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia","volume":"19","author":"Furtner","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101414_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1600-0609.2006.00679.x","article-title":"Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma","volume":"77","author":"Hentschel","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.xcrm.2024.101414_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"Vinay","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2024.101414_bib28","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T\u00a0cell proliferation and lead to the amplification in\u00a0vivo of cytotoxic T\u00a0cell responses","volume":"186","author":"Shuford","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2024.101414_bib29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.5483\/BMBRep.2014.47.3.283","article-title":"4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy","volume":"47","author":"Vinay","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.xcrm.2024.101414_bib30","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1078-0432.CCR-15-0263","article-title":"Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy","volume":"21","author":"Yonezawa","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib31","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1158\/0008-5472.CAN-17-0610","article-title":"Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand","volume":"77","author":"Kang","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib32","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41467-019-10088-1","article-title":"Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with Fc\u03b3R affinity","volume":"10","author":"Qi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101414_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101414_bib34","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1002\/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L","article-title":"CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils","volume":"30","author":"Heinisch","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib35","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.4049\/jimmunol.178.7.4194","article-title":"Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice","volume":"178","author":"Niu","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.xcrm.2024.101414_bib36","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/s41467-018-07136-7","article-title":"Structure of the 4-1BB\/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab","volume":"9","author":"Chin","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101414_bib37","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1538-7445.AM2022-2868","article-title":"Abstract 2868: ADG206, an anti-CD137 agonistic POWERbody\u08ea with tailor-made efficacy and safety profiles by strong crosslinking and tumor selective activation for single and combinational cancer immunotherapy","volume":"82","author":"Liu","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101414_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101414_bib39","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/138945012803530062","article-title":"Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials","volume":"13","author":"Ang","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.xcrm.2024.101414_bib40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nrc2870","article-title":"Envisioning the future of early anticancer drug development","volume":"10","author":"Yap","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101414_bib41","series-title":"Common Terminology Criteria for Adverse Events. Version 5.0","year":"2020"},{"key":"10.1016\/j.xcrm.2024.101414_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and Clarification: From the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer (Oxford, England : 1990)"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:00:46Z","timestamp":1733223646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666379124000375"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101414","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin\u2019s lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101414"}}